SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
The increase of stake in Aster DM Healthcare is a reiteration of the confidence in the business across geographies
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
lAIH strives to introduce appropriate interventions for nurturing an AMR innovation ecosystem in the country through cohesive efforts across the innovation pyramid
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
A total of 889 M&A deals were announced in the medical devices sector in 2022 worth $93 billion
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Subscribe To Our Newsletter & Stay Updated
